Overview of liposomes
- PMID: 1778891
- DOI: 10.1093/jac/28.suppl_b.39
Overview of liposomes
Abstract
Many of the problems associated with conventional drug therapy may be circumvented by the use of delivery systems which, in a variety of ways, will optimize drug action. Among the systems being investigated, liposomes hold considerable promise. Versatility in both the structural characteristics of liposomes and their ability to accommodate a wide range of drugs has contributed to the design of appropriate formulations with optimal pharmacological actions. Areas in which such formulations have been already applied successfully experimentally or clinically, include cancer chemotherapy, antimicrobial therapy and vaccines.
Similar articles
-
Liposomes in drug delivery. Clinical, diagnostic and ophthalmic potential.Drugs. 1993 Jan;45(1):15-28. doi: 10.2165/00003495-199345010-00003. Drugs. 1993. PMID: 7680982 Review.
-
The liposomal formulation of doxorubicin.Methods Enzymol. 2005;391:71-97. doi: 10.1016/S0076-6879(05)91004-5. Methods Enzymol. 2005. PMID: 15721375
-
Use of liposomes as injectable-drug delivery systems.Am J Hosp Pharm. 1989 Aug;46(8):1576-87. Am J Hosp Pharm. 1989. PMID: 2672806 Review.
-
Stabilization of liposomes during drying.Expert Opin Drug Deliv. 2011 Mar;8(3):375-88. doi: 10.1517/17425247.2011.553219. Epub 2011 Feb 4. Expert Opin Drug Deliv. 2011. PMID: 21294603 Review.
-
Pharmacology of drugs formulated with DepoFoam: a sustained release drug delivery system for parenteral administration using multivesicular liposome technology.Clin Pharmacokinet. 2006;45(12):1153-76. doi: 10.2165/00003088-200645120-00002. Clin Pharmacokinet. 2006. PMID: 17112293 Review.
Cited by
-
Comparative pharmacokinetics, distributions in tissue, and interactions with blood proteins of conventional and sterically stabilized liposomes containing 2',3'-dideoxyinosine.Antimicrob Agents Chemother. 1996 Jan;40(1):225-9. doi: 10.1128/AAC.40.1.225. Antimicrob Agents Chemother. 1996. PMID: 8787911 Free PMC article.
-
A species-specific approach to the use of non-antimony treatments for cutaneous leishmaniasis.Am J Trop Med Hyg. 2011 Jan;84(1):109-17. doi: 10.4269/ajtmh.2011.10-0437. Am J Trop Med Hyg. 2011. PMID: 21212212 Free PMC article.
-
Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies.Antimicrob Agents Chemother. 1997 Oct;41(10):2201-8. doi: 10.1128/AAC.41.10.2201. Antimicrob Agents Chemother. 1997. PMID: 9333048 Free PMC article. Clinical Trial.
-
Liposomal formulations of cytotoxic drugs.Support Care Cancer. 1996 Jul;4(4):298-304. doi: 10.1007/BF01358884. Support Care Cancer. 1996. PMID: 8829309 Review.
-
Liposomal Antioxidants for Protection against Oxidant-Induced Damage.J Toxicol. 2011;2011:152474. doi: 10.1155/2011/152474. Epub 2011 Aug 16. J Toxicol. 2011. PMID: 21876690 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources